Injectable poly-L-lactic acid (Sculptra): technical considerations in soft-tissue contouring

Area of Science:

• Dermatology
• Aesthetic Medicine
• Biomaterials

Background:

• Poly-L-lactic acid (PLLA) received FDA approval in 2004 for HIV-related facial lipoatrophy.
• PLLA is utilized for soft-tissue contouring in both on-label and off-label applications.
• This article aims to provide comprehensive guidance on PLLA reconstitution, injection, and complication management.

Purpose of the Study:

• To establish consensus-based recommendations for injectable PLLA treatment protocols.
• To outline techniques for achieving safer and more consistent outcomes with PLLA.
• To minimize the risks and potential complications associated with PLLA soft-tissue augmentation.

Main Methods:

• Consensus opinion derived from pooled experiences of the authors.
• Review of European and U.S. clinical experiences with PLLA.
• Development of a conservative treatment approach based on observed outcomes.

Main Results:

• Injectable PLLA has been used in Europe since 1999 for soft-tissue volumization.
• Early challenges in the U.S. included overaggressive use and inadequate dilution.
• Physicians can benefit from European experience to refine PLLA application techniques.

Conclusions:

• A conservative approach is recommended for PLLA treatment.
• Higher volume dilution (8-12 cc), fewer vials per session, and subcutaneous injection plane are advised.
• Adequate time between sessions (≥6 weeks) and post-injection massage are crucial for optimal results and complication avoidance.